UPDATE: Jefferies Starts Chimerix (CMRX) at Buy

March 31, 2021 6:43 AM EDT
Get Alerts CMRX Hot Sheet
Price: $6.14 -2.07%

Rating Summary:
    11 Buy, 7 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 8 | New: 9
Trade Now! 
Join SI Premium – FREE
(Updated - March 31, 2021 7:39 AM EDT)

Jefferies analyst Maury Raycroft initiates coverage on Chimerix (NASDAQ: CMRX) with a Buy rating and a price target of $21.00.

The analyst commented, "CMRX's pipeline is diversified w/ 3 legit shots value creation. CMRX's targeted-onc drugONC201 is currently in a pivotal w/ more data expected 2H21 -- could be on mkt for defined tumor type (small #pts but high unmet need) by 2023 (est ~$400M/yr). Also, antiviral brincidofovir for smallpox contract (we est ~$440M/5 yrs) Apr/May & PDUFA7/7/21. CMRX's DSTAT (ph.III in AML) is a large mkt, which we view as under appreciated for CMRX w/ long-term potential."

For an analyst ratings summary and ratings history on Chimerix click here. For more ratings news on Chimerix click here.

Shares of Chimerix closed at $8.59 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co, PDUFA